From PsychonautWiki
(Redirected from Pargylad)
Jump to navigation Jump to search
Summary sheet: PARGY-LAD
Chemical Nomenclature
Common names PARGY-LAD
Substitutive name 6-propynyl-6-nor-lysergic acid diethylamide,[1] N-Propynyl-nor-LSD,[1] N,N-Diethyl-6-propargyl-6-norlysergamide[1]
Systematic name (8β)-N,N-Diethyl-6-(prop-2-yn-1-yl)-9,10-didehydroergoline-8-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 50 - 125 µg
Light 125 - 275 µg
Common 275 - 500 µg
Strong 500 - 700 µg
Heavy 700 µg +
Total 6 - 8 hours
Onset 30 - 45 minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


6-Propynyl-6-nor- Lysergic acid diethylamide (also known as N-Propynylnorlysergic acid N,N-diethylamide[1], N-PropynylnorLSD[1] or simply PARGY-LAD[1]) is a novel synthetic psychedelic substance of the lysergamide chemical class that produces a similar albeit significantly less distinct array of LSD-like psychedelic effects when administered. It is a close structural homolog of LSD known mainly for its obscurity and lack of distinguishing features.[1]

PARGY-LAD was first briefly mentioned as an analog of LSD by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"). It has been reported to be significantly less potent than LSD itself with "some activity reported at 160 μg" and "full activity at 500 micrograms."[2]

Very little data exists about the pharmacological properties, metabolism, and toxicity of PARGY-LAD, and it has very little history of human usage. It has recently appeared on the market alongside research chemical psychedelic lysergamides such as AL-LAD, ETH-LAD and PRO-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors, and is considered to be one of the least popular and available in the series. It is highly advised to approach this unstudied hallucinogenic substance with the proper amount of precaution and harm reduction practices if choosing to use it.


Substitutive structure of a lysergamide.

PARGY-LAD, or 6-propynyl-6-nor-lysergic acid diethylamide, is a synthetic alkaloid of the lysergamide family. PARGY-LAD is a structural analog of lysergic acid, with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine).

PARGY-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, PRO-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton, this is represented by the nor- prefix. Instead, PARGY-LAD is substituted at R6 with a propynyl group.


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

PARGY-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from PARGY-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects


  • Cannabis - When used in conjunction with cannabis, both the visual and cognitive effects of PARGY-LAD can be intensified and extended with extreme efficiency. This should be used with caution if one is not experienced with psychedelics. Many users sometimes report a dramatically more intense visual trip when combining it with THC concentrates such as hashish as opposed to cannabis flower. However, this can also amplify the anxiety, confusion and psychosis producing aspects of both substances significantly, so extreme caution with this combination is advised.
  • Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of PARGY-LAD have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations and confusion.
  • Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration, nausea, and physical fatigue which can negatively affect a trip if taken in in moderate to dosages. This combination is however reasonably safe in low doses and when used responsibly, this can often take the edge off a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit more stressful on the body.
  • Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of a PARGY-LAD trip. They are very efficient at stopping bad trips at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with lower dosages than one would take for either substance individually.

Toxicity and harm potential

The toxicity and long-term health effects of recreational PARGY-LAD do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because PARGY-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried PARGY-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

While no formal studies have been conducted, PARGY-LAD is likely not habit-forming and it is reasonable to speculate that the desire to use it can actually decrease with repeated administration. As with most psychedelics, it likely possesses what is considered an intrinsic, self-regulating aspect to it.

Tolerance to the effects of PARGY-LAD are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). PARGY-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of PARGY-LAD all psychedelics will have a reduced effect.

Dangerous interactions

Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. Note that the substances listed below refer to LSD specifically; however, there is no reason to believe these negative interactions do not apply equally, if not even more so, to relatively unstudied and structurally similar compounds such as PARGY-LAD as well.

  • Tramadol - Tramadol has been documented as lowering the seizure threshold[3] and psychedelics may cause occasional seizures.[4][5][6]
  • Stimulants - Stimulants may provoke anxiety, thought loops or psychosis.[7]
  • Lithium - Individuals who take lithium for bipolar disorder or other psychiatric conditions should not take PARGY-LAD. There are numerous anecdotal reports of seizures and or unsafe psychosis from this combination with LSD.[8][9][10][11]



This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United Kingdom: As of January 7th, 2015, PARGY-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.[12]
  • Latvia - PARGY-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.[13]

See also

External links


  • Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409.
  • Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
  • Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Isomer Design. (n.d.). TiHKAL · info | explore | PARGY-LAD; N,N-Diethyl-6-propargyl-6-norlysergamide. Retrieved from
  2. Shulgin, A., & Shulgin, A. (1991). Erowid Online Books: "TIHKAL" - #51. PRO-LAD. Retrieved April 14, 2017.
  3. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  4. Tripsit Factsheets - LSD |
  5. Fisher, D. D., & Ungerleider, J. T. (1967). Grand mal seizures following ingestion of LSD. California Medicine, 106(3), 210. PMCID: PMC1502729
  6. Question ID: 2837 (Ask Erowid) |
  7. Tripsit Factsheets - LSD |
  8. | LSD Interactions by Erowid
  9. Wanderli. "A Nice Little Trip to the Hospital: An Experience with Lithium & LSD (ID 83935)". Oct 3, 2010.
  10. MissDja1a. "Having a Seizure and Passing Out: An Experience with Lithium & LSD (ID 75153)". Dec 16, 2008.
  11. Reddit account of seizure on LSD + Lithium |
  12. ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014. 
  13. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) |